Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Q4 Revenues Expected to Rise 66 Percent

NEW YORK – PerkinElmer said on Monday that it expects revenue growth of about 66 percent for the fourth quarter of 2020.

PerkinElmer posted total revenues of $805.5 million in Q4 2019.

Organically, revenue growth is anticipated to be around 63 percent for the three months ended Jan. 3, it said, while GAAP earnings per share from continuing operations are expected to be at least $2.88 and adjusted EPS from continuing operations are expected to be at least $3.60, well above the Wall Street consensus forecast of $2.79.

The Waltham, Massachusetts-based firm attributed its performance to better-than-expected demand for its COVID-19, as well as non-COVID-19 products. COVID-19-related products contributed about $535 million to revenues, while non-COVID-19 products declined about 3 percent organically.

The company is scheduled to release its Q4 financial results on Feb. 2.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.